Phil Gregory’s new gig looks a whole lot like his old gig. It’s just that, under the umbrella of Regeneron, things have ...

The U.S. FDA, the Environmental Protection Agency and the Department of Agriculture have answered the Biden administration’s ...

It was the summer of 2020. Pandemic aside, things were going well for Tuyen Ong, M.D. The physician and biotech entrepreneur ...

Takeda has made some cuts to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising candidates.  | Takeda has taken an ax ...

Conversations about clinical trial diversity have finally gone mainstream, but | Sponsors have struggled to improve diversity ...

American Clinical Research Services has purchased Elixia, a clinical trial network that specializes in studies involving ...

Sanofi Chief Scientific Officer and head of research Frank Nestle, M.D., is leaving the company. | Sanofi CSO Frank Nestle is leaving the company, a spokesperson confirmed. He joined the French pharma ...

Marinus Pharmaceuticals is implementing a raft of cost-cutting measures in the wake of last month's phase 3 struggles—including jettisoning a fifth of its workforce. Employees at the ...

Accelerated approval—controversial, yes—but absolutely necessary for small, pre-revenue biotechs trying to find new treatments for small patient populations. | Accelerated approval—controversial, ...

Johnson & Johnson MedTech’s Biosense Webster division is rolling out a new version of its heart-mapping system that the company says marks its first to employ artificial intelligence capabilities. The ...

Compass Pathways has navigated to another successful midphase readout, linking its psilocybin therapy and psychological support to improvements in post-traumatic stress disorder (PTSD) in a small ...

A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7 ...